VivoSeq
Cardiovascular

Systolic Heart Failure

24

Pipeline Programs↗

1

Active Trials↗

17

Companies Involved↗

Systolic Heart Failure is an emerging landscape with 24 programs across 17 companies. The most active players are Bristol-Myers Squibb, Salix, Viking Therapeutics, Inc.. 16 therapies are approved with 3 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

48/100

Pipeline Velocity

0/100

Mech. Concentration

14/100

Completion Rate

75/100

Attrition Rate

18/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 2S

Salix

1 program

Phase 2V

Viking Therapeutics, Inc.

1 program

Phase 2Tibotec Pharmaceuticals, Ireland logo

Tibotec Pharmaceuticals, Ireland

1 program

Phase 2M

Mezzion Pharma Co. Ltd

1 program

Phase 3Merck & Co. logo

Merck & Co.

2 programs

Approved

Pipeline

Programs by Phase

Analysis

Trial Status

17

clinical trials

Completed9 · 53%
Unknown status4 · 24%
Terminated3 · 18%
Enrolling by invitation1 · 6%

Clinical Trials

Trial Activity

17 trials

A Registry-based Cluster Randomized Trial to Compare the Effect of Spironolactone vs. Eplerenone on Clinical Outcomes in Patients With Symptomatic Systolic Heart Failure
Enrolling by invitation·—·Phase 4·NCT03984591·7,200 enrolled
Evaluate the Effect of Injectable Neucardin on the Cardiac Function of Subjects With Chronic Systolic Heart Failure
Completed·ZZensun Sci. & Tech. Co., Ltd.·Phase 3·NCT04468529·154 enrolled
Intravenous Iron in Patients With Systolic Heart Failure and Iron Deficiency to Improve Morbidity & Mortality
Completed·UUniversitätsklinikum Hamburg-Eppendorf·Phase 4·NCT03036462·1,105 enrolled
Evaluation of the Effect of Injectable Neucardin on Cardiac Function and Reversal Ventricular Remodeling in Patients With Chronic Systolic Heart Failure
Completed·ZZensun Sci. & Tech. Co., Ltd.·Phase 3·NCT05949801·202 enrolled
A Dose-Defining Study of CXL-1020 in Patients With Systolic Heart Failure
Completed·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 2·NCT01096043·69 enrolled
Treatment of Diabetes in Patients With Systolic Heart Failure
Completed·VVirginia Commonwealth University·Phase 4·NCT02920918·36 enrolled
Effects of Aliskiren, Ramipril, and the Combination on Levels of Angiotensin II in Patients With Decompensated Systolic Heart Failure
Completed·Novartis logoNovartis·Phase 2·NCT00923156·123 enrolled
Platelet Inhibition in Patients With Systolic Heart Failure
Completed·UUniversity of Nebraska·Phase 4·NCT01765400·30 enrolled
A Prospective, Open-labeled, Multi-centric Trial in Subjects With Systolic Heart Failure to Evaluate Bisoprolol Treatment for the Effects on Surrogate Markers of Heart Failure in Korea
Completed·Merck & Co. logoMerck & Co.·Phase 4·NCT01074307·180 enrolled
Nicotinamide Riboside in Systolic Heart Failure
Completed·UUniversity of Washington·Phase 1/2·NCT03423342·30 enrolled
Clinical Trial to Evaluate the Efficacy and Safety of Recombinant Human Neuregulin-1 for Subcutaneous Administration in Patients With Chronic Systolic Heart Failure
Terminated·ZZensun Sci. & Tech. Co., Ltd.·Phase 3·NCT01214096·15 enrolled
Study of Efficacy on Cardiac Remodeling of Recombinant Human Neuregulin-1 in Stable Chronic Systolic Heart Failure Patients
Terminated·ZZensun Sci. & Tech. Co., Ltd.·Phase 3·NCT01439893·14 enrolled
Udenafil Therapy to Improve Symptomatology, Exercise Tolerance and Hemodynamics in Patients With Chronic Systolic Heart Failure
Terminated·SSeoul National University Hospital·Phase 3·NCT01646515·41 enrolled
Clinical Trial of Systolic Heart Failure Treatment of IvabRadine Hemisulfate Sustained-release Tablets （FIRST）
Unknown status·JJiangsu HengRui Medicine Co., Ltd.·Phase 2/3·NCT02188082·336 enrolled
The Prognostic Impact of Using High-dose Hydralazine in Severe Systolic Heart Failure With Hemodynamically Significant Mitral Regurgitation
Unknown status·KKaohsiung Veterans General Hospital.·Phase 4·NCT04217135·400 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)